Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 74,292 shares, an increase of 32.0% from the November 30th total of 56,277 shares. Based on an average trading volume of 188,913 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are short sold. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 188,913 shares, the short-interest ratio is currently 0.4 days.
Chugai Pharmaceutical Stock Performance
Shares of CHGCY opened at $26.79 on Tuesday. The company’s 50-day simple moving average is $25.48 and its 200-day simple moving average is $24.11. Chugai Pharmaceutical has a 1 year low of $19.50 and a 1 year high of $31.26. The stock has a market capitalization of $88.17 billion, a PE ratio of 33.49 and a beta of 0.63.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its earnings results on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. The firm had revenue of $2.26 billion for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. On average, sell-side analysts predict that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
See Also
- Five stocks we like better than Chugai Pharmaceutical
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Your “birthright claim” just got activated
- Wall Street Stockpicker Names #1 Stock of 2026
- Terrifying reason Trump killed the U.S. penny?
- Turn your “dead money” into $306+ monthly (starting this month)
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
